natgillin/translations-raw huggingface dataset:
Kalydeco has been shown to improve lung function in patients aged six years and above who had one of nine CFTR gating mutationsandin patients aged 18 years and above who had an R117H mutation.
Zdravilo Kalydeco se je izkazalo za učinkovito pri izboljšanju pljučne funkcije pri bolnikih, starejših od šest let, ki so imeli eno od devetih mutacij spreminjanja prehodnosti v genu CFTR, in pri bolnikih, starejših od 18 let, ki so imeli mutacijo R117H.
Kalydeco is a medicine that contains the active substance ivacaftor.
Kalydeco je zdravilo, ki vsebuje zdravilno učinkovino ivakaftor.
Kalydeco is also indicated for the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene (see sections 4.4 and 5.1).
Zdravilo Kalydeco je indicirano tudi za zdravljenje bolnikov s cistično fibrozo (CF), starih 18 let ali več, ki imajo mutacijo R117H na genu CFTR (glejte poglavji 4.4 in 5.1).
Kalydeco is also indicated for the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene.
Zdravilo Kalydeco je indicirano tudi za zdravljenje bolnikov s cistično fibrozo (CF), starih18 let ali starejših, ki imajo mutacijo R117H na genu CFTR.
Kalydeco is always given in combination with the medicines you usually use.
Zdravilo Kalydeco se vselej daje v kombinaciji z zdravili, ki jih navadno uporabljate.
Kalydeco is always given in combination with the medicines your child usually uses.
Zdravilo Kalydeco se vselej daje v kombinaciji z zdravili, ki jih vaš otrok navadno uporablja.
Kalydeco is used to treat cystic fibrosis in patients aged 2 years and above who have one of nine mutations in the gene for the protein called ‘cystic fibrosis transmembrane conductance regulator’ (CFTR).
Zdravilo Kalydeco se uporablja za zdravljenje cistične fibroze pri bolnikih, starejših od dveh let, ki imajo eno od devetih oblik mutacije v genu za beljakovino, ki se imenuje cistično fibrozni transmembranski regulator prevodnosti (CFTR).
Kalydeco should be taken with fat-containing food.
Zdravilo Kalydeco je treba jemati z mastno hrano.
Kalydeco should only be prescribed by doctors with experience in the treatment of cystic fibrosis, and only patients confirmed to have one of the ten mutations mentioned above should be prescribed the medicine.
Zdravilo Kalydeco lahko predpiše samo zdravnik, ki ima izkušnje z zdravljenjem cistične fibroze, in sicer samo bolnikom, ki imajo potrjeno eno od opisanih desetih oblik mutacij.
Kalydeco should only be used during breast-feeding if the potential benefit outweighs the potential risk.
Zdravilo Kalydeco smemo v času dojenja uporabljati samo, če presodimo, da bo pričakovana korist odtehtala kakršnokoli morebitno tveganje.
Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).
Tablete Kalydeco so indicirane za zdravljenje bolnikov s cistično fibrozo (CF), starih 6 let ali več in s telesno maso 25 kg ali več, ki imajo eno od naslednjih mutacij spreminjanja prehodnosti kanalčkov celične membrane (skupina III) v genu CFTR (cystic fibrosis transmembrane conductance regulator): G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N ali S549R (glejte poglavji 4.4 in 5.1).
Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Tablete Kalydeco so indicirane za zdravljenje bolnikov s cistično fibrozo (CF), starih 6 let in starejših, ki tehtajo 25 kg ali več in imajo eno od naslednjih mutacij spreminjanja prehodnosti kanalčkov celične membrane na genu CFTR (cystic fibrosis transmembrane conductance regulator): G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N ali S549R.
Kalydeco tablets are not adequate for children under 6 years of age.
Tablete zdravila Kalydeco niso primerne za otroke, mlajše od 6 let.
Kalydeco was also effective in patients with mutations other than G551D.
Zdravilo Kalydeco je bilo učinkovito tudi pri bolnikih z drugimi oblikami mutacij kot G551D.
Kalydeco was compared with placebo in two main studies involving 219 patients with cystic fibrosis who had the G551D mutation.
Zdravilo Kalydeco so primerjali s placebom v dveh glavnih študijah, ki sta vključevali 219 bolnikov s cistično fibrozo, ki so imeli mutacijo v genu G551D.
Kalydeco was shown to be effective at improving lung function in patients with cystic fibrosis who had the G551D mutation.
Dokazano je bilo, da je zdravilo Kalydeco učinkovito pri izboljševanju delovanja pljuč pri bolnikih s cistično fibrozo, ki so imeli mutacijo G551D.
KANUMA 2 mg/ml concentrate for solution for infusion sebelipase alfa
KANUMA 2 mg/ml koncentrat za raztopino za infundiranje sebelipasum alfa
KANUMA 2 mg/ml sterile concentrate sebelipase alfa
KANUMA 2 mg/ml sterilni koncentrat
KANUMA at doses up to 1 mg/kg once weekly resulted in improvements in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and weight gain within the first several weeks of treatment.
Zdravilo KANUMA je v odmerkih do 1 mg/kg enkrat na teden izboljšalo ravni alanin- aminotransferaze (ALT) in aspartat-aminotransferaze (AST) in pridobivanje telesne mase v prvih nekaj tednih zdravljenja.
KANUMA has no or negligible influence on the ability to drive and use machines.
Zdravilo KANUMA ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
KANUMA is for intravenous use only.
Zdravilo KANUMA je samo za intravensko uporabo.
KANUMA is supplied as a concentrate for solution for infusion.
Zdravilo KANUMA je na voljo kot koncentrat za raztopino za infundiranje.
KANUMA should be prepared and used according to the following steps.
Zdravilo KANUMA je treba pripraviti in uporabiti v skladu z naslednjimi koraki.
Kaplan Meier estimates for time to first need for therapeutic ascites puncture are given in Figure 1.
Ocena po Kaplan Meierju za čas do prve potrebe po terapevtskem punktiranju ascitesa so predstavljene v Sliki 1.
Kaplan Meier estimates of the median duration of event-free survival were 35 months in the R-CHOP arm compared to 13 months in the CHOP arm, representing a risk reduction of 41 %.
Kaplan- Meierjeva ocena medianega trajanja preživetja brez dogodkov je bila 35 mesecev v skupini R-CHOP v primerjavi s 13 meseci v skupini CHOP; to pomeni zmanjšanje tveganja za dogodke za 41 %.
Kaplan Meier estimates within group
Kaplan-Meierjeve ocene znotraj skupine
Kaplan Meier plot of PFS
Kaplan-Meierjev prikaz PFS
Kaplan Meier plots of overall survival by histology
Čas preživetja (meseci) Čas preživetja (meseci)
Kaplan- Meier curves of investigator assessed overall survival (post-hoc analysis 20 May 2013) is presented in Figure 3.
Kaplan-Meierjeve krivulje celokupnega preživetja po oceni raziskovalcev (post-hoc analiza 20. maja 2013) so prikazane na sliki 3.
Kaplan--Meier Estimate of Median Time to Event (Months)
Kaplan-Meierjeva ocena mediane časa do dogodka (meseci)
Kaplan-Meier curve for OS for the ITT population is provided in Figure 2.
Krivulja celokupnega preživetja po Kaplan-Meier za ITT populacijo je na sliki 2.
Kaplan-Meier curve for PFS for the ITT population is provided in Figure 1.
Krivulja po Kaplan-Meier za PFS za populacijo ITT je na sliki 1.
Kaplan-Meier curve for PFS for the ITT population is provided in Figure 1.
Krivulja po Kaplan-Meier za PFS za populacijo ITT je na sliki.
Kaplan-Meier Curve of Time to Persistent 10% 6MWD Worsening
Kaplan-Meierjeva krivulja časa do persistentnega 10-odstotnega poslabšanja razdalje, prehojene v 6 minutah
Kaplan-Meier curves OS by treatment arm in randomised Phase 3 Study 1014 (full analysis population) in patients with previously untreated ALK-positive advanced NSCLC
Kaplan-Meierjeva krivulja za OS glede na skupino zdravljenja v randomizirani študiji 3. faze, Študiji 1014 (analiza celotne populacije) pri bolnikih s predhodno nezdravljenim ALK-pozitivnim napredovalim NSCLC
Kaplan-Meier Estimate of Median Time to Event (Months)
Kaplan-Meierjeva ocena medianega časa do dogodka (meseci)
Kaplan-Meier estimate, months a
Kaplan- Meierjeva ocena, meseci a
Kaplan-Meier estimates
Ocena po Kaplan- Meierjevi metodi
Kaplan-Meier estimates of 18-month survival for each study are shown below.
Ocena 18-mesečnega preživetja po metodi Kaplan- Meier za obe študiji je prikazana spodaj.
Kaplan-Meier estimates of survival were 90% and 85% at 3 and 4 years after the start of treatment, respectively.
Ocena preživetja po metodi Kaplan- Meier je bila 90 % 3 leta in 85 % 4 leta po začetku zdravljenja.
Kaplan-Meier estimates of survival were 90% and 85% at 3 and 4 years after the start of treatment, respectively.
Ocena preživetja po metodi Kaplan-Meier je bila 90 % 3 leta in 85 % 4 leta po začetku zdravljenja.
Kaplan-Meier medians
Kaplan-Meierjeve mediane
Kaplan‐Meier Estimate of Median Time to Event (Months)
Kaplan-Meierjeva ocena mediane časa do dogodka (meseci)
Kaposi’s sarcoma (a cancer of the blood vessels) in patients with acquired immune deficiency syndrome (AIDS) who have very damaged immune systems and extensive sarcoma on the skin, the moist body surfaces or the internal organs; multiple myeloma (a cancer of the cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already undergone or are unsuitable for a bone marrow transplant.
Kaposijevega sarkoma (raka žil) pri bolnikih s sindromom pridobljene imunske pomanjkljivosti (aidsom), ki imajo zelo prizadet imunski sistem in razširjen sarkom na koži, vlažnih telesnih površinah ali notranjih organih; multiplega mieloma (raka celic v kostnem mozgu) pri bolnikih z napredujočo boleznijo, ki so prejeli najmanj eno drugačno terapijo in so že prestali presaditev kostnega mozga ali zanjo niso primerni.
Karvea 150 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Karvea 150 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Karvea 150 mg film-coated tablets.
Karvea 150 mg filmsko obložene tablete.
Karvea 300 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Karvea 300 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Karvea 300 mg film-coated tablets.
Karvea 300 mg filmsko obložene tablete.
Karvea 75 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Karvea 75 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Karvea 75 mg film-coated tablets.
Karvea 75 mg filmsko obložene tablete.
Karvea can be taken with or without food.
Zdravilo Karvea lahko jemljete s hrano ali brez nje.
Karvea in combination with aliskiren- containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Karvea se v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), ne sme uporabljati pri bolnikih s sladkorno boleznijo ali zmerno do hudo ledvično okvaro.
Karvea is for oral use.
Zdravilo Karvea je potrebno zaužiti.
Karvea is used in adult patients
Zdravilo Karvea uporabljamo pri odraslih bolnikih:
Karvea slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 zdravilo Karvea upočasni pešanje delovanja ledvic.
Karvea with food and drink
Jemanje zdravila Karvea skupaj s hrano in pijačo
Karvea with food and drink
Zdravila Karvea skupaj s hrano in pijačo
Karvea with food and drink
Zdravilo Karvea skupaj s hrano in pijačo
Karvea with food and drink
ZdraviloKarvea skupaj s hrano in pijačo
Karvezide 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Zdravilo Karvezide 150 mg/12,5 mg je namenjeno bolnikom, pri katerih se zvišan krvni tlak med zdravljenjem samo s hidroklorotiazidom ali samo s 150 mg irbesartana ni dovolj znižal.
Karvezide 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Karvezide 150 mg/12.5 mg.
Zdravilo Karvezide 300 mg/12,5 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem s 300 mg irbesartana ali z zdravilom Karvezide 150 mg/12,5 mg ni dovolj znižal.
Karvezide 300 mg/25 mg may be administered in patients insufficiently controlled by Karvezide 300 mg/12.5 mg.
Zdravilo Karvezide 300 mg/25 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem z zdravilom Karvezide 300 mg/12,5 mg ni dovolj znižal.
Karvezide can be taken once daily, with or without food.
Bolniki lahko zdravilo Karvezide jemljejo enkrat na dan skupaj s hrano ali brez nje.
Karvezide can be taken with or without food.
Zdravilo Karvezide lahko jemljete skupaj s hrano ali brez nje.
Karvezide is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Zdravilo Karvezide je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
Karvezide is for oral use.
Zdravilo Karvezide je potrebno zaužiti.
Karvezide should not be given to children and adolescents (under 18 years).
Zdravila Karvezide otroci in mladostniki (mlajši od 18 let) ne smejo jemati.
Karvezide should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Zdravilo Karvezide se pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) ne sme uporabljati (glejte poglavje 4.3).
Karvezide with food and drink
Zdravilo Karvezide skupaj s hrano in pijačo
Kawasaki disease (major signs of the illness are for instance: fever, skin rash, swollen lymph glands, inflammation and rash of the mucous membranes of the mouth and throat)
Kawasakijeva bolezen (pomembnejši znaki bolezni so npr.: povišana telesna temperatura, izpuščaj na koži, otekle bezgavke, vnetje in izpuščaj na sluznicah ust in žrela).
Kawasaki disease, an illness in children where the blood vessels (arteries) in the body become enlarged.
Kawasakijev sindrom, otroška bolezen, pri kateri se v telesu povečajo krvne žile (arterije).
Kawasaki disease, which causes multiple inflammations of several organs in the body;
Kawasakijeve bolezni, ki povzroča večkratno vnetje več organov v telesu;
Kawasaki disease.
Kawasakijev sindrom.
Kawasaki disease.
Kawasakijevem sindromu.
Kawasaki disease.
Kawasakijevi bolezni.
Kd = Kyprolis plus dexamethasone; Vd = bortezomib plus dexamethasone; OS = overall survival; mo = months; NE = Not Estimable; HR = hazard ratio; CI = confidence interval
Kd = Kyprolis in deksametazon, Vd = bortezomib in deksametazon, OS = celokupno preživetje, NO = ni ocenljivo, HR = razmerje ogroženosti, IZ = interval zaupanja.
Kd = Kyprolis plus dexamethasone; Vd = bortezomib plus dexamethasone; PFS = progression-free survival; mo = months; HR = hazard ratio; CI = confidence interval;
Kd = Kyprolis in deksametazon, Vd = bortezomib in deksametazon, PFS = preživetje brez napredovanja, HR = razmerje ogroženosti, IZ = interval zaupanja.
keep
hranite
Keep a note of where you have injected each week
Vsak teden si zabeležite, kam ste zdravilo injicirali.
Keep a record of your injection
Vodite evidenco o injiciranju zdravila
Keep and store the opened diluent bottle under aseptic conditions because it is needed for dilution of the concentrate.
Odprte steklenice z vehiklom shranjujte pod aseptičnimi pogoji, ker boste vehikel potrebovali za redčenje koncentrata.
Keep any remaining unused syringes in their original carton, in the refrigerator.
Preostale, še neuporabljene napolnjene injekcijske brizge z varovalom za iglo pustite v hladilniku v originalni ovojnini.
Keep away from heat, sparks, open flame or other source of ignition.
Hranite ga stran od vročine, isker, odprtega ognja ali drugih virov vžiga.
Keep away from naked flames.
Zavarujte pred odprtim ognjem.
Keep bottle tightly closed in order to protect from moisture.
Vsebnik shranjujte tesno zaprt za zagotovitev zaščite pred vlago.
Keep breathing in even after you have heard the inhaler “CLICK” to be sure you get the full dose.
Z vdihovanjem nadaljujte, tudi če ste že zaslišali »KLIK« inhalatorja, da tako prejmete celoten odmerek.
Keep breathing in even after you have heard the inhaler “CLICK” to be sure you get the full dose.
Z vdihovanjem nadaljujte, tudi če ste že zaslišali „KLIK“ inhalatorja, da tako prejmete celoten odmerek.
Keep cartridges in the outer carton in order to protect from light.
Vložke shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Keep children away from faeces, urine or the vomit of treated dogs.
Otroci ne smejo priti v stik z iztrebki, urinom ali izbruhano vsebino zdravljenih psov.
Keep container in the outer carton in order to protect it from light.
Vsebnik shranite v zunanji škatli za zagotovitev zaščite pred svetlobo.
Keep container tightly closed in order to protect from moisture.
Vsebnik shranjujte tesno zaprt za zagotovitev zaščite pred vlago.
keep discard
hranite zavrzite
Keep Discard
Shranite Zavrzite
Keep eating enough carbohydrates.
Še naprej uživajte dovolj ogljikovih hidratov.
Keep enough pressure on the skin and press the button with your thumb.
Dovolj čvrsto pritiskajte na kožo in s palcem pritisnite gumb.
Keep filled syringe in your hand and do not touch syringe tip.
Napolnjeno brizgo držite v roki in se ne dotikajte konice brizge.
Keep GANFORT out of the sight and reach of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep holding the pen firmly against your skin.
Injekcijski peresnik še naprej močno pritiskajte v kožo.
Keep holding your thumb on the button and then slowly count to 5 to deliver the full dose of the medicine.
Držite palec na gumbu in počasi preštejte do 5, da si boste dali celotni odmerek zdravila.
Keep in mind that increased exposure to UV light will contribute to skin cancer development.
Ne pozabite, da bo povečana izpostavljenost UV-svetlobi prispevala k razvoju kožnega raka.
Keep in outer carton in order to protect from light.
Shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Keep in touch with your doctor, and do not stop taking Combivir without your doctor’s advice.
Bodite v stiku z vašim zdravnikom in ne prenehajte jemati zdravila Combivir brez zdravnikovega nasveta.
Keep in touch with your doctor, and do not stop taking Epivir without your doctor’s advice.
Bodite v stiku z zdravnikom in ne prenehajte jemati zdravila Epivir brez zdravnikovega nasveta.
Keep in touch with your doctor, and do not stop taking Kivexa without your doctor’s advice.
Bodite v stiku s svojim zdravnikom in ne nehajte jemati zdravila Kivexa brez zdravnikovega nasveta.
Keep in touch with your doctor, and do not stop taking Lamivudine/Zidovudine Teva without your doctor’s advice.
Bodite v stiku z vašim zdravnikom in ne prenehajte jemati zdravila Lamivudin/zidovudin Teva brez zdravnikovega nasveta.
Keep in touch with your doctor, and do not stop taking Ziagen without your doctor’s advice.
Bodite v stiku s svojim zdravnikom in ne prenehajte jemati zdravila Ziagen brez zdravnikovega nasveta.
Keep injection sites covered with airtight and watertight dressings at all times.
Mesta injiciranj naj bodo ves čas pokrita z neprodušnim in nepremočljivim povojem.
Keep it dry.
Pazite, da bo vedno ostal suh.
Keep it safely
Shranite ga na varnem.
Keep it safely.
Shranite ga na varnem.
Keep it straight as you screw on.
Ko jo privijate, jo držite naravnost.
keep keep
hranite
Keep new pens in a fridge, at 2°C to 8°C.
Nove peresnike shranjujte v hladilniku na temperaturi od 2 do 8 °C.
Keep out of reach and sight of children
Zdravilo shranjujte nedosegljivo otrokom.
Keep out of reach and sight of children.
Shranjujte nedosegljivo otrokom.
Keep out of reach and sight of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of reach and sight of children.
Zdravilo shranjujte nedosegljivo otrokom.
Keep out of reach of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of sight and reach of children.
Shranjujte nedosegljivo otrokom
Keep out of sight and reach of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the r sight and reach of children.
Zdravilo shranjujte nedosegljivo otrokom.
Keep out of the reach and sight of children
Cepivo shranjujte nedosegljivo otrokom
Keep out of the reach and sight of children
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the reach and sight of children
Zdravilo shranjujte nedosegljivo otrokom.
Keep out of the reach and sight of children.
Cepivo shranjujte nedosegljivo otrokom
Keep out of the reach and sight of children.
Cepivo shranjujte nedosegljivo otrokom.
Keep out of the reach and sight of children.
Inhalator shranjujte nedosegljiv otrokom
Keep out of the reach and sight of children.
Kontrastno sredstvo shanjujte nedosegljivo otrokom
Keep out of the reach and sight of children.
Kontrastno sredstvo shranjujte nedosegljivo otrokom
Keep out of the reach and sight of children.
SHRANJEVANJE FORCALTONINA Zdravilo shranjujte zunaj dosega in pogleda otrok.
Keep out of the reach and sight of children.
Zdravilo shranjujete nedosegljivo otrokom
Keep out of the reach and sight of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the reach and sight of children.Accidental ingestion should be regarded as serious.
Vsako nenamerno zaužitje obravnavajte kot zelo resno.
Keep out of the sight and raech of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the sight and reach and children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the sight and reach and of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the sight and reach of children
Cepivo shranjujte nedosegljivo otrokom
Keep out of the sight and reach of children
Shranjujte nedosegljivo otrokom.
Keep out of the sight and reach of children
Zdravilo shranjujte nedosegljivo otrokom
Keep out of the sight and reach of children
Zdravilo shranjujte nedosegljivo otrokom.
Keep out of the sight and reach of children, preferably in a locked cupboard.
Zdravilo shranjujte nedosegljivo otrokom, najbolje v zaklenjeni omarici.
Keep out of the sight and reach of children, preferably in a locked cupboard.
Zdravilo shranjujte nedosegljivo otrokom, po možnosti v zaklenjeni omari .
Keep out of the sight and reach of children, preferably in a locked cupboard.
Zdravilo shranjujte nedosegljivo otrokom, po možnosti v zaklenjeni omari.
Keep out of the sight and reach of children.
. Zdravilo shranjujte nedosegljivo otrokom
Keep out of the sight and reach of children.
amnezija, hiperkinezija, nenaden nepremagljiv spanec, sinkopa
Keep out of the sight and reach of children.
Cepivo shranjujte nedosegljivo otrokom
Keep out of the sight and reach of children.
Shranjujte nedosegljivo in pogleda otrokom.
Keep out of the sight and reach of children.
Zdravilo shranjujete nedosegljivo otrokom.
Keep out of the sight and reach of children.
Zdravilo shranjujte izven dosega in pogleda otrok.
Keep out of the sight and reach of children.
Zdravilo shranjujte izven pogleda in dosega otrok.
Keep out of the sight and reach of children.
Zdravilo shranjujte nedosegljivo otrokom in izven njihovega vidnega polja
Keep out of the sight and reach of children.
Zdravilo shranjujte nedosegljivo otrokom in izven vidnega polja otrok
Keep out of the sight and reach of children.
Zdravilo shranjujte nevidno in nedosegljivo otrokom
Keep out of the sight and reach of children.
Zdravilo shranjujte zunaj pogleda in dosega otrok
Keep out of the sight and reach of children.
Zdravilop shranjujte nedosegljivo otrokom.
Keep out of the sight and reachof children.
Shranjujte nedosegljivo otrokom.
Keep out of the sight and reachof children.
Zdravilo shranjujte nedosegljivo otrokom.
Keep out of the sight and sight of children.
Zdravilo shranjujte nedosegljivo otrokom